Full history for every metric is available with a Kvantra account
Torii Pharmaceutical Co., Ltd. (4551.T)
Key financial summary
Financials in JPY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥bn | 43 | 42 | 47 | 49 | 55 | 60 | 63 |
| Operating profit | ¥bn | 7 | 7 | |||||
| Net profit | ¥bn | 27 | 3 | 3 | 4 | 4 | 5 | 5 |
| EPS reported | ¥ | 179.4 | 192.4 | |||||
| Operating cashflow per share | ¥ | 129.5 | 0.00 | |||||
| Capex per share | ¥ | 5.41 | 0.00 | |||||
| FCF per share | ¥ | 124.1 | 0.00 | |||||
| Free cash flow | ¥bn | 3 | 0 | |||||
| Net debt | ¥bn | -48 | -34 | |||||
| Book value equity | ¥bn | 122 | 122 | |||||
| Book value per share | ¥ | 4,324 | 4,357 | |||||
| Number of shares | m | 28.11 | 28.11 | |||||
| DPS (TTM paid) | ¥ | 60.00 | 0.00 |
Financial summary
Financials in JPY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2,099,083.75 | 1.46 | |||||
| P/S LTM | x | 4,221,824.13 | 2.81 | |||||
| P/FCF LTM | x | 73,159,720.33 | 0.00 | |||||
| EV/EBITDA LTM | x | 36,743,182.26 | 19.19 | |||||
| EV/Sales LTM | x | 4,221,823.63 | 2.28 | |||||
| Earnings Yield LTM | % | 0.00% | 1.45% | |||||
| FCF Yield | % | 0.00% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | 4.15% | 2.12% | |||||
| ROIC | % | 4.16% | 1.91% | |||||
| Operating margin | % | 11.25% | 10.04% | |||||
| Gross margin | % | 43.86% | 43.87% | |||||
| FCF/Sales | % | 5.77% | 0.00% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +22.38% | +2.93% | |||||
| Sales Growth YoY | % | +10.59% | +10.91% | |||||
| Net Income Growth YoY | % | +22.41% | +2.95% | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | +35.01% | +2.13% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | -53.85% | -100.00% | |||||
| Payout Ratio | % | 72.47% | 0.00% | |||||
| FCF/Debt | x | 8.13 | - | |||||
| Net Debt/EBITDA | x | -4.37 | -1.35 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -0.00% | -18.95% | |||||
| Net debt/Equity | x | -0.39 | -0.28 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Operating within Japan, Torii Pharmaceutical Co., Ltd. specializes in the development and commercialization of various medicinal products. Its product lineup includes Riona, an agent for treating hyperphosphatemia, and REMITCH, an oral medication addressing pruritus in patients with dialysis-related or liver conditions. The company also provides ANTEBATE, an anti-inflammatory drug prescribed for skin ailments like atopic and contact dermatitis. Additionally, their portfolio features allergen immunotherapy tablets, specifically CEDARCURE and MITICURE, along with CORECTIM, a topical janus kinase (JAK) inhibitor. Torii Pharmaceutical primarily promotes these offerings to healthcare professionals through its dedicated team of medical representatives. Founded in 1872 as Torii Shoten K.K., the company officially became Torii Pharmaceutical Co., Ltd. in May 1949. It is headquartered in Tokyo, Japan, and operates as a subsidiary of Japan Tobacco Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Torii Pharmaceutical Co., Ltd. (4551.T)
Operating within Japan, Torii Pharmaceutical Co., Ltd. specializes in the development and commercialization of various medicinal products. Its product lineup includes Riona, an agent for treating hyperphosphatemia, and REMITCH, an oral medication addressing pruritus in patients with dialysis-related or liver conditions. The company also provides ANTEBATE, an anti-inflammatory drug prescribed for skin ailments like atopic and contact dermatitis. Additionally, their portfolio features allergen immunotherapy tablets, specifically CEDARCURE and MITICURE, along with CORECTIM, a topical janus kinase (JAK) inhibitor. Torii Pharmaceutical primarily promotes these offerings to healthcare professionals through its dedicated team of medical representatives. Founded in 1872 as Torii Shoten K.K., the company officially became Torii Pharmaceutical Co., Ltd. in May 1949. It is headquartered in Tokyo, Japan, and operates as a subsidiary of Japan Tobacco Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free